Ionis Launches Phase 3 Trial of Donidalorsen for Preventing Attacks
Ionis Pharmaceuticals has launched a registrational Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational therapy donidalorsen, formerly known as IONIS-PKK-LRx, in people with hereditary angioedema (HAE) types 1 and 2. While the trial, called OASIS-HAE, may already be recruiting, information on recruitment status…